Reactive Infectious Mucocutaneous Eruption: A Rising Enigma
DOI:
https://doi.org/10.20344/amp.22792Keywords:
Exanthema, Mucositis, Mycoplasma pneumoniaeAbstract
Reactive infectious mucocutaneous eruption is a rare condition that predominantly occurs in pediatric patients following a respiratory infection, most commonly caused by Mycoplasma pneumoniae. It is characterized by prominent mucositis, usually with minimal or absent skin involvement. We present the case of a nine-year-old male admitted with severe oral mucositis and a penile lesion compromising bladder emptying. During hospitalization, dispersed cutaneous lesions emerged along with bilateral conjunctival hyperemia. The etiological investigation detected Mycoplasma pneumoniae in respiratory secretions, with positive IgM and IgG serology. Treatment included azithromycin, intravenous immunoglobulin and methylprednisolone, resulting in progressive clinical improvement. This case highlights the importance of recognizing reactive infectious mucocutaneous eruption. It can be challenging to differentiate from Stevens-Johnson syndrome, but it tends to have a more favorable clinical course. Early initiation of supportive care and multidisciplinary support are crucial for a good prognosis.
Downloads
References
González C, Croche B, Gómez E. Reactive Infectious mucocutaneous eruption (RIME) in paediatric patients: extrapulmonary mycoplasma pneumoniae involvement. Rev Esp Quimioter. 2024;37:518-20.
Mahama A, Kojder P, Thibodeaux Q. Reactive infectious mucocutaneous eruption following COVID-19 in an adolescent boy: case report and review of the literature. Pediatr Dermatol. 2022;40:162-5.
Bowe S, O’Connor C, Gleeson C, Murphy M. Reactive infectious mucocutaneous eruption in children diagnosed with COVID-19. Pediatr Dermatol. 2021;38:1385-6.
Farhan R, Salim S, Surani A. reactive infectious mucocutaneous eruption (RIME) in COVID-19. WMJ. 2023;122:368-71.
Ramien M, Goldman JL. Pediatric SJS-TEN: where are we now? F1000Res. 2020;9:982.
Vassalo C, Calabria VR, Isoletta E, Biscarini S, Filippo AD, Brazzelli V. Clinical and microbiological characteristics of reactive Infectious mucocutaneous eruption: a case of 5 patients. JAAD Case Rep. 2021;17:152-6.
Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae–induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239-45.
Gonçalves R, Gata L, Brett A. Mycoplasma pneumoniae-associated mucositis. BMJ Case Rep. 2021;14:e239086.
Centers for Disease Control and Prevention. Mycoplasma pneumoniae infections have been increasing. 2024 [cited 2024 Oct 18]. Available from: https://www.cdc.gov/ncird/whats-new/mycoplasma-pneumoniae-infections-have-been-increasing.html.
Bolluyt DC, Euser SM, Souverein S, Rossum AM, Kalpoe J, Westreenen M, et al. Increased incidence of mycoplasma pneumoniae infections and hospital admissions in the Netherlands, november to december 2023. Euro Surveill. 2024;29:2300724.
Maredia H, Eseonu A, Grossberg AL, Cohen BA. Recurrent mycoplasma pneumoniae-associated reactive infectious mucocutaneous eruption responsive to systemic steroids: a case series. JAAD Case Rep. 2021;11:139-43.
Ramien ML. Reactive infectious mucocutaneous eruption: mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol. 2021;46:420.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

